COMP <GO>
ANAB vs ABBV // EV/EBITDA & P/E VALUATION
AnaptysBio Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ANAB 4
— ABBV 5
▲ EV/EBITDA & P/E VALUATION LEADER: ANAB
LAST: $48.64 (-3.68%) • MKT CAP: $1.44B
valuation
5.7x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANAB VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANAB | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 29.00% | +56.00 | ANAB | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 5.7x | 33.3x | -27.60 | ANAB | /valuation <GO> |
| Free Cash Flow Yield | 1.36% | 3.47% | -2.11 | ABBV | /fcf-yield <GO> |
| Operating Margin | 75.00% | 24.60% | +50.40 | ANAB | /operating-margins <GO> |
| Net Profit Margin | -5.60% | 6.90% | -12.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 157.00% | 8.60% | +148.40 | ANAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 65.1 | -18.36 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.44B | $513.86B | -$512.42B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANAB REV | ABBV REV | ANAB GROSS % | ABBV GROSS % | ANAB FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $234.6M | $61.16B | — | 70.2% | $19.6M | $17.82B |
| FY 2024 | $91.3M | $56.33B | — | 70.0% | -$135.7M | $17.83B |
| FY 2023 | $17.2M | $54.32B | — | — | -$120.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANAB // BETA —
ABBV // BETA 1.15